-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

Benzinga·08/25/2026 12:31:41
语音播报
Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.